Chronotherapeutic oral drug absorption system verapamil is effective in reducing morning blood pressure in African Americans: A post hoc analysis of the chrono trial

Journal of the National Medical Association

Volumn 97, Issue 3, 2005, Pages 377-383

  Prisant, L Michael ^a,b,c   Weber, Michael ^b,d   Black, Henry R ^e  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b Department of Medicine ^*  (United States)

^c Hypertension and Clin Pharmacol U   (United States)

^d SUNY DOWNSTATE MEDICAL CENTER   (United States)

^e RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

African Americans; Chronotherapy; Hypertension; Verapamil

Indexed keywords

VERAPAMIL;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BLOOD PRESSURE; CHRONOTHERAPY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG ABSORPTION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; ETHNIC GROUP; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RACE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

ADMINISTRATION, ORAL; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; CALCIUM CHANNEL BLOCKERS; CHRONOTHERAPY; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; VERAPAMIL;

EID: 14644406219     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. American Heart Association. Statistical Fact Sheet-Populations: African Americans and Cardiovascular Disease. 2004. http://www.american heart.org/presenter.jhtml?identifier=3000927. Accessed 11/03/04.
2. Douglas JG, Bakris GL, Epstein M, et al. Management of high blood pressure in African Americans. Consensus statement of the Hypertension in African Americans Working Group of the International Society of Hypertension in Blacks. Arch Int Med. 2003;163:525-541.
3. Cubeddu LX, Arand J, Singh B, et al. A comparison of verapamil and propranolol for the initial treatment of hypertension. Racial differences in response. JAMA. 1986;256:2214-2221.
4. Saunders E, Weir MR, Kong W, et al. A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Int Med. 1990;150:1707-1713.
5. Sareli P, Radvevski IV, Valtchanova Z, et al. Efficacy of different drug classes used to initiate antihypertensive treatment in black subjects. Arch Int Med. 2001;161:965-971.
6. Bakris G, Sica D, Ram V, et al. A comparative trial of controlled-onset, extended-release verapamil, enalapril and losartan on blood pressure and heart rate changes. Am J Hypertens. 2002;15:53-57.
7. White WB, Johnson MF, Black HR, et al. Effects of chronotherapeutic delivery of verapamil on circadian blood pressure in African-American patients with hypertension. Ethn Dis. 1999;9:341-349.
8. Prisant LM, Black HR, Messerli F, et al. A community-based hypertension trial of a chronotherapeutic formulation of verapamil. Am J Ther. 2002;9:476-483.
9. Hall WD. A rational approach to the treatment of hypertension in special populations. Am Fam Physician. 1999;60:156-162.
10. Chobanian AV, Bakris GL, Black HR, et al. The 7th Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC 7 Report. JAMA. 2003;289:2560-2576.
11. Bakris G, Mangrum A, Copley JB, et al. Effect of calcium channel blockade or beta blockade on the progression of diabetic nephropathy in African Americans. Hypertens. 1997;29:744-750.
12. Pepine CJ, Handberg EM, Cooper-DeHoff R, et al. A calcium antagonist vs. a noncalcium antagonist hypertension treatment strategy for patients with coronary artery disease. JAMA. 2003;290:2805-2816.
13. Giles TD, Bakris GL, Smith DHG, et al. Defining the antihypertensive properties of the angiotensin receptor blocker telmisartan by a practice-based clinical trial. Am J Hypertens. 2003;16:460-466.